The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 28, 2014
Filed:
Oct. 28, 2004
John Randall Swart, Orange City, IA (US);
Eric Martin Vaughn, Ames, IA (US);
Karen E. Freking, Hospers, IA (US);
Michael B. Roof, Ames, IA (US);
Phillip Wayne Hayes, Maurice, IA (US);
Reid C. Phillips, Parkville, MO (US);
John Randall Swart, Orange City, IA (US);
Eric Martin Vaughn, Ames, IA (US);
Karen E. Freking, Hospers, IA (US);
Michael B. Roof, Ames, IA (US);
Phillip Wayne Hayes, Maurice, IA (US);
Reid C. Phillips, Parkville, MO (US);
Boehringer Ingelheim Vetmedica, Inc., St. Joseph, MO (US);
Abstract
The present invention provides a composition and an improved single dose vaccine againstand an improved single dose vaccine againstandwhich provides one or more of the following: 1) confers effective immunity againstand/or; 2) decreases the risk of developing clinical signs ofand/orinfection; 3) induces an immune response againstand/or; and 4) has a DOI againstand/orof at least four months. The composition orvaccine as well as the combined-composition or vaccine each includes a bacterial component of inactivatedbacteria and a suitable adjuvant. The combined-composition or vaccine further includes an amount ofantigen. The vaccines can be administered to animals in any conventional manner. The amount of the dose for intramuscular administration is preferably less than 5 ml. The amount ofand/orantigen in each dose should be enough to induce an immune response in the animal receiving the vaccine or composition and will preferably confer effective immunity against and decrease the risk of developing clinical signs resulting fromand/orinfection for a suitable duration of immunity.